Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$0.28	$0.34	$0.22 ▼ $2.54	$17.36M	0.75	2.73 million shs	795,197 shs
RUBY Rubius Therapeutics	$0.06	$0.04	$0.00 ▼ $0.38	$5.16M	2.59	1.15 million shs	755,858 shs
SABS SAB Biotherapeutics	$1.78	$1.70	$1.00 ▼ $5.01	$16.53M	0.55	66,838 shs	8,148 shs
XFOR X4 Pharmaceuticals	$2.82 +2.9%	$4.03	$2.62 ▼ $31.20	$15.86M	0.67	121,142 shs	245,896 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	0.00%	-11.73%	-15.15%	-34.38%	-86.07%
RUBY Rubius Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SABS SAB Biotherapeutics	0.00%	-5.32%	-1.11%	+11.95%	-31.01%
XFOR X4 Pharmaceuticals	+2.92%	-11.88%	-3.42%	-69.12%	-90.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGTX Cognition Therapeutics	3.6087 of 5 stars	3.5	5.0	0.0	0.0	2.8	1.7	1.3
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	3.4953 of 5 stars	3.5	5.0	0.0	0.0	2.2	1.7	1.3
XFOR X4 Pharmaceuticals	4.7547 of 5 stars	3.5	2.0	0.0	4.6	2.5	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGTX Cognition Therapeutics	3.00	Buy	$5.63	1,908.93% Upside
RUBY Rubius Therapeutics	0.00	N/A	N/A	N/A
SABS SAB Biotherapeutics	3.00	Buy	$13.25	644.38% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$72.33	2,465.01% Upside

Current Analyst Ratings Breakdown

Latest RUBY, CGTX, XFOR, and SABS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/15/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/2/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $7.00
4/1/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/27/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/26/2025	XFOR X4 Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00
3/24/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
3/21/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	$0.17 per share	N/A
SABS SAB Biotherapeutics	$1.32M	12.53	N/A	N/A	$2.81 per share	0.63
XFOR X4 Pharmaceuticals	$2.56M	6.38	N/A	N/A	$3.90 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGTX Cognition Therapeutics	-$33.97M	-$0.74	N/A	N/A	N/A	N/A	-194.42%	-115.14%	8/6/2025 (Estimated)
RUBY Rubius Therapeutics	-$179.67M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	-$34.10M	-$3.70	N/A	N/A	N/A	N/A	-105.14%	-69.24%	8/6/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	$2.14	1.32	N/A	N/A	46.54%	-181.56%	-54.36%	8/6/2025 (Estimated)

Latest RUBY, CGTX, XFOR, and SABS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	SABS SAB Biotherapeutics	-$1.00	-$0.56	+$0.44	-$0.56	$0.13 million	N/A
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million
3/28/2025	Q4 2024	SABS SAB Biotherapeutics	-$1.16	-$1.23	-$0.07	-$1.23	$0.12 million	$0.05 million
3/25/2025	Q4 2024	XFOR X4 Pharmaceuticals	-$5.10	-$6.00	-$0.90	-$0.20	$1.07 million	$1.43 million
3/20/2025	Q4 2024	CGTX Cognition Therapeutics	-$0.16	-$0.17	-$0.01	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
RUBY Rubius Therapeutics	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGTX Cognition Therapeutics	N/A	2.09	2.09
RUBY Rubius Therapeutics	N/A	N/A	N/A
SABS SAB Biotherapeutics	0.15	1.69	1.69
XFOR X4 Pharmaceuticals	3.30	3.70	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGTX Cognition Therapeutics	43.35%
RUBY Rubius Therapeutics	N/A
SABS SAB Biotherapeutics	7.82%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
CGTX Cognition Therapeutics	14.40%
RUBY Rubius Therapeutics	5.30%
SABS SAB Biotherapeutics	27.77%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGTX Cognition Therapeutics	20	61.99 million	53.07 million	Not Optionable
RUBY Rubius Therapeutics	6	90.48 million	85.69 million	Not Optionable
SABS SAB Biotherapeutics	140	9.29 million	6.71 million	Not Optionable
XFOR X4 Pharmaceuticals	80	5.79 million	5.65 million	Optionable

RUBY, CGTX, XFOR, and SABS Headlines

Recent News About These Companies

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16 at 8:00 AM | globenewswire.com

Cantor Fitzgerald Predicts XFOR FY2026 Earnings

June 13, 2025 | americanbankingnews.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30, 2025 | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30, 2025 | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30, 2025 | benzinga.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30, 2025 | insidermonkey.com

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26, 2025 | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 26, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RUBY, CGTX, XFOR, and SABS Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

$0.28 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+1.79%)

As of 06/18/2025 07:51 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Rubius Therapeutics NASDAQ:RUBY

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$1.75 -0.03 (-1.74%)

As of 06/18/2025 04:00 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

X4 Pharmaceuticals NASDAQ:XFOR

$2.82 +0.08 (+2.92%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.82 0.00 (-0.04%)

As of 06/18/2025 07:56 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time